Disc Medicine
IRON

$48.11

0.97%

Market Cap: $1.43B

About: Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.

Employees: 78

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

83% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 30

61% more call options, than puts

Call options by funds: $1.59M | Put options by funds: $986K

60% more funds holding in top 10

Funds holding in top 10: 5 [Q1] → 8 (+3) [Q2]

5.76% more ownership

Funds ownership: 90.8% [Q1] → 96.56% (+5.76%) [Q2]

7% less capital invested

Capital invested by funds: $1.39B [Q1] → $1.29B (-$101M) [Q2]

8% less funds holding

Funds holding: 130 [Q1] → 120 (-10) [Q2]

26% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 38

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$57

18%

upside

Avg. target

$71

48%

upside

High target

$85

77%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

Cantor Fitzgerald Kristen Kluska 54% 1-year accuracy 54 / 100 met price target	77%upside $85	Overweight Reiterated	20 Sept 2024
HC Wainwright & Co. Douglas Tsao 56% 1-year accuracy 79 / 142 met price target	46%upside $70	Buy Reiterated	16 Sept 2024
Wells Fargo Tiago Fauth 69% 1-year accuracy 9 / 13 met price target	56%upside $75	Overweight Initiated	22 Aug 2024
Wedbush David Nierengarten 56% 1-year accuracy 35 / 63 met price target	18%upside $57	Outperform Reiterated	9 Aug 2024
HC Wainwright & Co. Douglas Tsao 56% 1-year accuracy 79 / 142 met price target	46%upside $70	Buy Reiterated	10 Jul 2024

See Analyst Rankings

Financial journalist opinion

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

Dr. Steve Caffé is an accomplished industry executive with over 25 years of expertise in global product development and regulatory affairs Dr. Steve Caffé is an accomplished industry executive with over 25 years of expertise in global product development and regulatory affairs

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences:

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Disc Medicine, Inc. released positive results from the phase 2 AURORA study, using bitopertin for the treatment of patients with EPP and XLP. Potential FDA feedback to initiate a pivotal study using bitopertin for the treatment of patients with EPP and XLP expected in the 2nd half of 2024. Results from the phase 1/2 study, using DISC-0974 for the treatment of patients with NDD-CKD, expected in the 2nd half of 2024.

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Disc Medicine Announces Underwritten Offering of Common Stock

WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an underwritten offering of 4,944,000 shares of its common stock at a price of $36.00 per share. The aggregate gross proceeds to Disc from this offering are expected to be approximately $178.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities being sold in the offering are being offered by Disc. The offering is expected to close on June 17, 2024, subject to the satisfaction of customary closing conditions.

Disc Medicine Announces Underwritten Offering of Common Stock

Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress

WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced positive additional data for bitopertin in erythropoietic protoporphyria (EPP), including additional analyses of AURORA data that further demonstrated the clinical activity of bitopertin and highlighted meaningful improvements in light tolerance, phototoxic reactions, and quality of life. Additionally, Disc shared updated data from a Phase 1b trial of DISC-0974 in MF anemia which demonstrated durable increases in hemoglobin and reduced transfusion burden in a majority of evaluable patients. Disc also shared initial SAD data from a Phase 1 healthy volunteer trial of DISC-3405 that provided proof of mechanism, showing that the drug has the potential to provide deep and sustained increases in hepcidin and reductions in iron. The data were presented at the European Hematology Association (EHA) 2024 Congress.

Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress

Disc Medicine to Participate in the Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will give a corporate presentation at the Jefferies Global Healthcare Conference on Thursday, June 6th at 1:00 pm ET.

Disc Medicine to Participate in the Jefferies Global Healthcare Conference

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress

WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its hematology portfolio at the upcoming European Hematology Association (EHA) 2024 Congress, which will be held in Madrid Spain on June 13-16, 2024.

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress

Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference

WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Monday, May 20th at 10:30 am ET.

Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

WATERTOWN, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the first quarter ended March 31, 2024.

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

Zacks Investment Research

Disc Medicine (IRON) Down on Mixed Results From AURORA Study

Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.

Disc Medicine (IRON) Down on Mixed Results From AURORA Study

See News Rankings